Pfizer Inc. $PFE Shares Sold by Koss Olinger Consulting LLC

Key Points

• Koss Olinger Consulting LLC cut its Pfizer stake by 52.9% in the fourth quarter, selling 41,718 shares and leaving it with 37,150 shares valued at about $925,000.
• Pfizer has been getting attention for pipeline progress, including a global oncology collaboration with Innovent Biologics worth up to $10.5 billion and long-term positive data from its LORBRENA CROWN trial.
• The stock remains a mixed analyst story: Wall Street’s consensus rating is Hold with an average target price of $28.82, while Pfizer also recently reported better-than-expected quarterly earnings and a 6.6% dividend yield.

Koss Olinger Consulting LLC lessened its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 52.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,150 shares of the biopharmaceutical company's stock after selling 41,718 shares during the period. Koss Olinger Consulting LLC's holdings in Pfizer were worth $925,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Norges Bank purchased a new stake in shares of Pfizer in the 4th quarter valued at $1,830,986,000. Franklin Resources Inc. raised its holdings in shares of Pfizer by 47.8% in the 3rd quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock valued at $638,787,000 after buying an additional 8,108,887 shares during the period. Vanguard Group Inc. raised its holdings in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock valued at $13,479,520,000 after buying an additional 7,031,162 shares during the period. Neuberger Berman Group LLC raised its holdings in shares of Pfizer by 203.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock valued at $229,346,000 after buying an additional 6,045,763 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in shares of Pfizer by 48.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock valued at $468,174,000 after buying an additional 5,978,927 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a major global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The deal gives Pfizer access to 12 early-stage cancer programs and expands its cancer pipeline, which investors may see as a long-term growth driver. Article Title
• Positive Sentiment: Pfizer reported seven-year follow-up data from its LORBRENA CROWN trial, showing the longest progression-free survival reported to date in advanced ALK-positive non-small cell lung cancer. Strong late-stage clinical evidence can support the drug’s commercial outlook and reinforce Pfizer’s oncology franchise. Article Title
• Positive Sentiment: Several reports highlighted progress in Pfizer’s clinical pipeline, including updates tied to lung cancer and obesity programs. Investors often reward pipeline milestones because they can improve future revenue potential and diversify growth beyond existing products. Article Title
• Neutral Sentiment: Commentary on insider activity suggested Pfizer insiders are not buying shares aggressively at current levels, but the article framed that as a lack of negative signal rather than a warning sign. This is more of a valuation/sentiment note than a direct catalyst. Article Title
• Neutral Sentiment: Additional items referenced early-stage trial updates and a real-world lung cancer study on dacomitinib. These are constructive for the pipeline, but they are still early and likely less material than the Innovent deal or the LORBRENA data. Article Title

Wall Street Analyst Weigh In

Several research firms recently issued reports on PFE. Barclays began coverage on Pfizer in a report on Thursday, February 19th. They issued an "underweight" rating and a $25.00 price objective on the stock. Zacks Research upgraded Pfizer from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 24th. CICC Research began coverage on Pfizer in a report on Thursday, April 16th. They issued an "outperform" rating and a $33.00 price objective on the stock. Wolfe Research reiterated an "underperform" rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Finally, Royal Bank Of Canada reiterated an "underperform" rating and issued a $25.00 price objective on shares of Pfizer in a report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $28.82.

Pfizer Trading Up 0.2%

NYSE:PFE opened at $26.18 on Friday. The stock has a 50-day simple moving average of $26.77 and a 200-day simple moving average of $26.28. The stock has a market cap of $149.23 billion, a P/E ratio of 19.99 and a beta of 0.35. Pfizer Inc. has a 1 year low of $23.06 and a 1 year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analysts' expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio is currently 131.30%.

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.